Viewing nowBalosartan Tablet 40mg (Valsartan)
Valsartan 40mg
Tablet · Prescription medication
Dong-A ST Co., Ltd.

MFDS item code 201105144 · Notified 2011.08.09 · Insurance code 642506620
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to control essential hypertension. It also helps relieve symptoms in heart failure patients who cannot tolerate ACE inhibitors. It is effective in reducing the risk of death in stable patients with reduced left ventricular function following myocardial infarction. In other words, this medication is used for hypertension, certain types of heart failure, and to reduce the risk of complications after myocardial infarction.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. It is recommended to take the medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: For patients with intravascular volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, start treatment with 40 mg of this drug once daily; do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, because there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this drug. 5. Patients with hepatic impairment: The daily dose of this drug for patients with mild to moderate hepatic impairment should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension 6) Children: The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age. 6. Children: The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to this medication, pregnant or breastfeeding women, those with severe liver or kidney disease, and patients with certain hereditary disorders should not take this medication. Elderly patients or those with high potassium levels, patients with impaired liver function, and those with heart or vascular problems need to consult their doctor before taking this medication. During treatment, blood pressure may drop suddenly, so immediate medical attention is required if symptoms such as dizziness or fainting appear. Patients with heart failure or post-myocardial infarction may experience changes in kidney function, so regular check-ups are necessary. Caution is required when driving or operating machinery as this medication has blood pressure-lowering effects, and interactions may occur when combined with other medications. Taking potassium-sparing diuretics or potassium supplements can dangerously elevate blood potassium levels, so caution is needed. This medication is not recommended for breastfeeding women, and if it is absolutely necessary to take it, breastfeeding should be discontinued. Safety and efficacy have not been established for children or adolescents under 18 years of age, so it should be avoided for these age groups. In case of overdose, severe hypotension, decreased consciousness, etc., may occur, requiring immediate emergency treatment. This medication should be kept out of reach of children, and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from entering, and kept in a cool place below 30 degrees Celsius. Therefore, it is advisable to avoid direct sunlight or high temperatures and humid places.
Yellow oval-shaped film-coated tablet
30 tablets (10 tablets/PTP x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 40mg
Tablet · Prescription medication
Dong-A ST Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.